1,000 volunteers injected with the home-grown vaccine Nanocovax in third-phase trials have developed antibodies against COVID-19, according to a report by Nanogen Pharmaceutical Biotechnology JSC, the vaccine producer.
The report was reviewed by the Ministry of Health, whose representatives confirmed that the Nanocovax vaccine is safe and of high immunity.
However, data about the duration of protective immunity of this vaccine is still unknown and therefore needs more research. The Ministry of Health also asked Nanogen to submit reports on the research results from the second and third trials before August 15th for possible approval of the vaccine for emergency use.
According to Nanogen Pharmaceutical, Nanocovax is a protein subunit vaccine, which developed and produced protein subunit vaccines by using recombinant S-protein subunit binding to silica nanoparticles. A subunit vaccine contains harmless antigen fragments (proteins) of SARS-CoV-2 and elicits an appropriate immune response, it added.
